Isoniazid

Generic Name: Isoniazid

Brand Names: Isonarif, Isotamine, Isotamine B, Rifamate, Rifater

Drug Type: Small Molecule

Chemical Formula: C_₆H_₇N_₃O

CAS Number: 54-85-3

Unique Ingredient Identifier: V83O1VOZ8L

Background: Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.

Indication: Isoniazid is used for the treatment of all forms of tuberculosis in which organisms are susceptible. It is also used in combination with rifampin and pyrazinamide.

Associated Conditions: Active Tuberculosis, Mycobacterium kansasii infection, Late phase Tuberculosis

Clinical Trials

Evaluation of Diabetes Control and Effect on Transmission and Development of Tuberculosis

Phase 4

Withdrawn

Conditions: Latent Tuberculosis
Diabetes Mellitus

Interventions: Drug: Isoniazid 300Mg Tab
Drug: Isoniazid 300 MG

First Posted Date: 2018-04-13

Last Posted Date: 2018-04-17

Lead Sponsor: Instituto Nacional de Salud Publica, Mexico

Registration Number: NCT03498534

Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis

Phase 2

Completed

Conditions: Tuberculosis, Pulmonary

Interventions: Drug: Rifampicin
Drug: Isoniazid
Drug: Pyrazinamide
Drug: Ethambutol
Drug: Linezolid
Drug: Clofazimine
Drug: Rifapentine
Drug: Levofloxacin
Drug: Bedaquiline

First Posted Date: 2018-03-22

Last Posted Date: 2023-08-14

Lead Sponsor: University College, London

Target Recruit Count: 675

Registration Number: NCT03474198

Locations: 🇮🇩
Saiful Anwar Hospital, Malang, Indonesia
🇺🇬
Joint Clinical Research Centre, Mbarara, Uganda
🇺🇬
Infectious Diseases Institute, Kampala, Uganda

and more 14 locations

Phase 2a Study of PBTZ169

Phase 2

Terminated

Conditions: Tuberculosis

Interventions: Drug: PBTZ169
Drug: Isoniazid

First Posted Date: 2017-11-07

Last Posted Date: 2020-03-09

Lead Sponsor: Nearmedic Plus LLC

Target Recruit Count: 16

Registration Number: NCT03334734

Alcohol Drinkers' Exposure to Preventive Therapy for TB (ADEPTT)

Phase 4

Completed

Conditions: Tuberculosis
HIV/AIDS
Alcohol Abuse

Interventions: Drug: Isoniazid 300 Mg ORAL TABLET
Drug: Pyridoxine 25 Mg Oral Tablet

First Posted Date: 2017-10-05

Last Posted Date: 2023-10-19

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 302

Registration Number: NCT03302299

Locations: 🇺🇬
Mbarara University of Science and Technology/Mbarara Regional Referral Hospital, Mbarara, Uganda

Efficacy, Security, Adherence, Tolerability and Cost Effectiveness of Latent TB Treatment in Patients With TB/DM2 (TBL)

Phase 4

Completed

Conditions: Tuberculin (Skin Test) Positive
Diabetes Mellitus

Interventions: Drug: Rifampin 600 mg Oral Tablet
Drug: Isoniazid 300 mg Oral Tablet

First Posted Date: 2017-09-11

Last Posted Date: 2019-04-26

Lead Sponsor: Instituto Nacional de Salud Publica, Mexico

Target Recruit Count: 396

Registration Number: NCT03278483

Locations: 🇲🇽
Instituto Nacional de Ciencias Medicas y Nutrición, Mexico City, Mexico

Treatment of Latent Tuberculosis in Socially Marginalised Citizens

Phase 4

Terminated

Conditions: Compliance, Patient

Interventions: Drug: Rifapentine
Drug: Isoniazid

First Posted Date: 2017-08-30

Last Posted Date: 2023-10-12

Lead Sponsor: Aarhus University Hospital

Target Recruit Count: 22

Registration Number: NCT03266991

Locations: 🇩🇰
Dept of Pulmonary Medicine, Esbjerg, Denmark

Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings

Not Applicable

Completed

Conditions: HIV/AIDS
Tuberculosis
Hepatitis
Addiction
Opioid Dependence

Interventions: Drug: Isoniazid
Drug: Methadone
Drug: Rifapentine

First Posted Date: 2017-03-24

Last Posted Date: 2024-10-04

Lead Sponsor: Yale University

Target Recruit Count: 1702

Registration Number: NCT03089983

Locations: 🇲🇾
Kajang Prison, Kajang, Selangor, Malaysia

Prevention of Tuberculosis in Prisons

Phase 4

Terminated

Conditions: Tuberculosis, Pulmonary
Antibiotic Prophylaxis

Interventions: Drug: Isoniazid 900 milligrams
Drug: Placebo

First Posted Date: 2017-01-23

Last Posted Date: 2019-10-25

Lead Sponsor: Federal University of Mato Grosso

Target Recruit Count: 467

Registration Number: NCT03028129

Locations: 🇧🇷
Roberto Oliveira, Dourados, Mato Grosso Do Sul, Brazil

Evaluation of the Effect of 3HP vs Periodic 3HP vs 6H in HIV-Positive Individuals

Phase 3

Completed

Conditions: HIV
Tuberculosis

Interventions: Drug: rifapentine + isoniazid
Drug: Isoniazid

First Posted Date: 2016-12-02

Last Posted Date: 2019-10-30

Lead Sponsor: The Aurum Institute NPC

Target Recruit Count: 4027

Registration Number: NCT02980016

Locations: 🇿🇦
The Aurum Institute NPC, Johannesburg, Gauteng, South Africa

Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis

Phase 4

Conditions: Tuberculosis, Pulmonary

Interventions: Drug: Isoniazid
Drug: Rifampicin
Drug: Pyrazinamide
Drug: Ethambutol
Drug: Levofloxacin

First Posted Date: 2016-09-15

Last Posted Date: 2017-03-20

Lead Sponsor: Beijing Chest Hospital

Target Recruit Count: 3900

Registration Number: NCT02901288

Locations: 🇨🇳
The Infectious Hospital of Hebi, Hebi, Henan, China
🇨🇳
Wuhan Institute For Tuberculosis Control, Wuhan, Hubei, China
🇨🇳
Anhui Chest Hospital, Hefei, Anhui, China

and more 32 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy